Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • bispecific antibody

    - PMLiVE

    MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

    Approximately 43,000 people are diagnosed with lung cancer every year in the UK

    - PMLiVE

    BMS shares overall survival results for Opdivo in phase 3 lung cancer trial

    More than 200,000 people are diagnosed with lung cancer in the US every year

    - PMLiVE

    J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

    Alterations in EGFR are among the most common driver mutations in lung cancer patients

    - PMLiVE

    Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial

    EGFR-activating mutations occur in up to 38% of all NSCLC tumours globally

    - PMLiVE

    J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study

    Alterations in EGFR are among the most common driver mutations in NSCLC patients

    - PMLiVE

    J&J’s Rybrevant/Lazcluze combination approved by FDA as first-line lung cancer treatment

    Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

    - PMLiVE

    Johnson & Johnson’s Rybrevant recommended by CHMP for pre-treated advanced NSCLC

    Non-small lung cancer accounts for up to 85% of all lung cancer cases

    - PMLiVE

    AstraZeneca’s Imfinzi regimen approved by MHRA to treat resectable lung cancer

    The drug is now approved in Great Britain to treat both resectable and unresectable NSCLC

    - PMLiVE

    Johnson & Johnson’s Rybrevant granted EC approval for first-line NSCLC use

    The drug was previously approved by the EU regulator for use after the failure of platinum-based therapy

    - PMLiVE

    Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer

    Non-small cell lung cancer represents up to 85% of all lung cancer diagnoses

    - PMLiVE

    AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study

    Datopotamab deruxtecan demonstrated a clinically meaningful overall survival improvement in NSCLC patients

    - PMLiVE

    J&J’s Rybrevant combination recommended by CHMP to treat advanced lung cancer

    The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links